Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Antiangiogenics Linked to Fatal Bleeds After RT in “Ultracentral” Lung Tumors
Key clinical point: In patients with tumors bordering the central airway, use of antiangiogenic agents has been linked to fatal hemorrhage after stereotactic body radiation therapy.
Major finding: There were 6 fatal pulmonary hemorrhages, of which 4 occurred in patients receiving bevacizumab or pazopanib within 30 days of stereotactic body radiation therapy.
Study details: A retrospective case series including 88 patients with lung tumors abutting the proximal bronchial tree or a planned target volume overlapping the esophagus.
Disclosures: Partial support came from the National Institutes of Health, the China Scholarship Council, and the Joanne & John Dallepezze Foundation. The investigators reported disclosures related to AstraZeneca, CivaTech Oncology, Alpha Tau Medical, Varian Medical Systems, Boehringer Ingelheim, Pfizer, Merck, and Elekta.
Wu AJ et al. JAMA Oncol. 2019 Apr 4. doi: 10.1001/jamaoncol.2019.0205.